Company / SG&A Expense
Tvardi Therapeutics, Inc. SG&A Expense History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$30.3M
FY2024
5-year range
$15.3M / $30.3M
FY2020-FY2024
Trend
+2.9%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
SG&A Expense has increased for 9 consecutive years, from $4M in FY2015 to $30M in FY2024.
Based on SEC 10-K filings.
$30M in FY2024 with a 5-year CAGR of +20.6%.
Increased from $22M to $30M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +19.5%
- 5-Year CAGR
- +20.6%
- 10-Year CAGR
- -
Key checks
Key Insights
- Tvardi Therapeutics, Inc.'s sg&a expense has grown for 9 consecutive years.
- 5-year CAGR of +20.6%, indicating consistent growth.
- In FY2024, sg&a expense increased 2.9% year-over-year.
- Lowest sg&a expense in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $30.3M | +2.9% |
| FY2023 | $29.4M | +34.6% |
| FY2022 | $21.8M | +23.1% |
| FY2021 | $17.7M | +15.8% |
| FY2020 | $15.3M | +29.0% |
| FY2019 | $11.9M | +28.6% |
| FY2018 | $9.2M | +18.8% |
| FY2017 | $7.8M | +25.7% |
| FY2016 | $6.2M | +75.8% |
| FY2015 | $3.5M | +24.3% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026